1. Home
  2. RNA
  3. RNA News

Latest Avidity Biosciences Inc. (RNA) News on April 2, 2025

Avidity Biosciences to Participate in Upcoming Investor Conference
RNA

PR Newswire

21 hours ago

Avidity Biosciences to Participate in Upcoming Investor Conference

RNA

MT Newswires

2 days ago

Avidity Completes Enrollment in Del-brax Trial's Biomarker Group for Facioscapulohumeral Muscular Dystrophy

Avidity Biosciences Completes Enrollment in Biomarker Cohort in Phase 1/2 FORTITUDE™ Trial for Delpacibart Braxlosiran (del-brax) in People Living with Facioscapulohumeral Muscular Dystrophy
RNA

PR Newswire

2 days ago

Avidity Biosciences Completes Enrollment in Biomarker Cohort in Phase 1/2 FORTITUDE™ Trial for Delpacibart Braxlosiran (del-brax) in People Living with Facioscapulohumeral Muscular Dystrophy

Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
RNA

PR Newswire

12 days ago

Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

RNA

MT Newswires

16 days ago

Sector Update: Health Care Stocks Decline Premarket Monday

RNA

MT Newswires

16 days ago

Sector Update: Health Care

RNA

MT Newswires

16 days ago

Avidity Biosciences Reports Positive Topline Data From Phase 1/2 Trial of Del-Zota to Treat DMD

Avidity Biosciences Announces Positive Topline Del-zota Data Demonstrating Consistent, Statistically Significant Improvements in Dystrophin, Exon Skipping and Creatine Kinase in People Living with Duchenne Muscular Dystrophy Amenable to Exon 44 Skipping in Phase 1/2 EXPLORE44® Trial
RNA

PR Newswire

16 days ago

Avidity Biosciences Announces Positive Topline Del-zota Data Demonstrating Consistent, Statistically Significant Improvements in Dystrophin, Exon Skipping and Creatine Kinase in People Living with Duchenne Muscular Dystrophy Amenable to Exon 44 Skipping in Phase 1/2 EXPLORE44® Trial

RNA

MT Newswires

20 days ago

Citigroup Initiates Avidity Biosciences Inc at Buy With $70 Price Target

RNA

MT Newswires

21 days ago

Avidity Biosciences Insider Sold Shares Worth $602,614, According to a Recent SEC Filing

Avidity Biosciences Announces Upcoming Presentations at the Muscular Dystrophy Association (MDA) Clinical & Scientific Conference
RNA

PR Newswire

21 days ago

Avidity Biosciences Announces Upcoming Presentations at the Muscular Dystrophy Association (MDA) Clinical & Scientific Conference

RNA

MT Newswires

21 days ago

BMO Capital Initiates Avidity Biosciences at Outperform With $72 Price Target

Avidity Biosciences Full Year 2024 Earnings: Revenues Beat Expectations, EPS In Line
RNA

Simply Wall St.

a month ago

Avidity Biosciences Full Year 2024 Earnings: Revenues Beat Expectations, EPS In Line

Avidity Biosciences Honors Rare Disease Day® and Global Efforts to Support People and Families Impacted by Rare Neuromuscular Diseases
RNA

PR Newswire

a month ago

Avidity Biosciences Honors Rare Disease Day® and Global Efforts to Support People and Families Impacted by Rare Neuromuscular Diseases

RNA

MT Newswires

a month ago

RBC Cuts Price Target on Avidity Biosciences to $61 From $67, Keeps Outperform, Speculative Risk

Avidity Biosciences, Inc. (RNA) Reports Q4 Loss, Tops Revenue Estimates
RNA

Zacks

a month ago

Avidity Biosciences, Inc. (RNA) Reports Q4 Loss, Tops Revenue Estimates

Avidity Biosciences to Participate in Upcoming Investor Conferences
RNA

PR Newswire

a month ago

Avidity Biosciences to Participate in Upcoming Investor Conferences

Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
RNA

PR Newswire

a month ago

Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

We're Hopeful That Avidity Biosciences (NASDAQ:RNA) Will Use Its Cash Wisely
RNA

Simply Wall St.

2 months ago

We're Hopeful That Avidity Biosciences (NASDAQ:RNA) Will Use Its Cash Wisely

Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
RNA

PR Newswire

2 months ago

Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Avidity Biosciences, Inc. (RNA): The Biotech Stock with Biggest Upside Potential
RNA

Insider Monkey

3 months ago

Avidity Biosciences, Inc. (RNA): The Biotech Stock with Biggest Upside Potential

Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
RNA

PR Newswire

3 months ago

Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

RNA

MT Newswires

3 months ago

Avidity Biosciences Plans to Submit First Biologics License Application This Year

Avidity Biosciences Plans First BLA Submission and Accelerates Commercialization Preparations for Three Rare Muscle Disease Programs in 2025
RNA

PR Newswire

3 months ago

Avidity Biosciences Plans First BLA Submission and Accelerates Commercialization Preparations for Three Rare Muscle Disease Programs in 2025

Why Is Avidity Biosciences, Inc. (RNA) Among the Best Multibagger Stocks to Buy Right Now?
RNA

Insider Monkey

3 months ago

Why Is Avidity Biosciences, Inc. (RNA) Among the Best Multibagger Stocks to Buy Right Now?

Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
RNA

PR Newswire

3 months ago

Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

RNA

MT Newswires

3 months ago

HC Wainwright Initiates Coverage on Avidity Biosciences With Buy Rating, $72 Price Target

RNA

MT Newswires

3 months ago

Avidity Biosciences Insider Sold Shares Worth $1,040,384, According to a Recent SEC Filing

RNA

MT Newswires

3 months ago

Avidity Biosciences Insider Sold Shares Worth $831,605, According to a Recent SEC Filing

Avidity Biosciences to Participate in Upcoming Investor Conference
RNA

PR Newswire

4 months ago

Avidity Biosciences to Participate in Upcoming Investor Conference

RNA

MT Newswires

4 months ago

RBC Initiates Avidity Biosciences at Outperform, Speculative Risk With $67 Price Target

Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
RNA

PR Newswire

4 months ago

Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Biotech Stock Roundup: NVAX Q3 Results, SNDX Down on AML Data, RNA Surges on Study Data
RNA

Zacks

5 months ago

Biotech Stock Roundup: NVAX Q3 Results, SNDX Down on AML Data, RNA Surges on Study Data

RNA Stock Hits Record High on Entering the Cardiac Disease Space
RNA

Zacks

5 months ago

RNA Stock Hits Record High on Entering the Cardiac Disease Space

Avidity Bio Has Surged 416% This Year — And That's Before Today's 'Game-Changing' News
RNA

Investor's Business Daily

5 months ago

Avidity Bio Has Surged 416% This Year — And That's Before Today's 'Game-Changing' News

Avidity Biosciences Announces New Precision Cardiology Development Candidates to Treat Rare Genetic Cardiomyopathies and Provides First Look at Next-Generation Technology Innovations
RNA

PR Newswire

5 months ago

Avidity Biosciences Announces New Precision Cardiology Development Candidates to Treat Rare Genetic Cardiomyopathies and Provides First Look at Next-Generation Technology Innovations

Avidity Biosciences Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag
RNA

Simply Wall St.

5 months ago

Avidity Biosciences Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag

Avidity Biosciences, Inc. (RNA) Reports Q3 Loss, Lags Revenue Estimates
RNA

Zacks

5 months ago

Avidity Biosciences, Inc. (RNA) Reports Q3 Loss, Lags Revenue Estimates

Avidity Biosciences Reports Third Quarter 2024 Financial Results and Recent Highlights
RNA

PR Newswire

5 months ago

Avidity Biosciences Reports Third Quarter 2024 Financial Results and Recent Highlights

Analysts Estimate Avidity Biosciences, Inc. (RNA) to Report a Decline in Earnings: What to Look Out for
RNA

Zacks

5 months ago

Analysts Estimate Avidity Biosciences, Inc. (RNA) to Report a Decline in Earnings: What to Look Out for

An RNAi renaissance is creating a new generation of startups
RNA

BioPharma Dive

5 months ago

An RNAi renaissance is creating a new generation of startups

Avidity Biosciences to Host Investor and Analyst Event Focused on Precision Cardiology Candidates and First Look at Next-Generation Technology Innovations on November 12, 2024
RNA

PR Newswire

5 months ago

Avidity Biosciences to Host Investor and Analyst Event Focused on Precision Cardiology Candidates and First Look at Next-Generation Technology Innovations on November 12, 2024

Avidity Biosciences Pursues Potential Accelerated Approval Path with Initiation of Biomarker Cohort in FORTITUDE™ Trial for Delpacibart Braxlosiran (del-brax/AOC 1020) in People Living with Facioscapulohumeral Muscular Dystrophy
RNA

PR Newswire

5 months ago

Avidity Biosciences Pursues Potential Accelerated Approval Path with Initiation of Biomarker Cohort in FORTITUDE™ Trial for Delpacibart Braxlosiran (del-brax/AOC 1020) in People Living with Facioscapulohumeral Muscular Dystrophy

Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
RNA

PR Newswire

5 months ago

Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Avidity Biosciences, Up 441%, Nears Another Record High As Dystrophy Space Heats Up
RNA

Investor's Business Daily

5 months ago

Avidity Biosciences, Up 441%, Nears Another Record High As Dystrophy Space Heats Up

RNA

MT Newswires

6 months ago

Avidity Biosciences Insider Sold Shares Worth $1,349,259, According to a Recent SEC Filing

Why Avidity Biosciences Zoomed to a 12% Gain This Week
RNA

Motley Fool

6 months ago

Why Avidity Biosciences Zoomed to a 12% Gain This Week

FDA lifts clinical hold on Avidity’s lead antibody conjugate therapy trial
RNA

Pharmaceutical Technology

6 months ago

FDA lifts clinical hold on Avidity’s lead antibody conjugate therapy trial

RNA

MT Newswires

6 months ago

Sector Update: Health Care Stocks Steady Premarket Thursday

RNA

MT Newswires

6 months ago

Avidity Biosciences Says FDA Lifted Partial Hold on Investigational Therapy for Neuromuscular Disease

Avidity Biosciences Announces FDA Removed Partial Clinical Hold on Delpacibart Etedesiran (del-desiran/AOC 1001)
RNA

PR Newswire

6 months ago

Avidity Biosciences Announces FDA Removed Partial Clinical Hold on Delpacibart Etedesiran (del-desiran/AOC 1001)

Is Avidity Biosciences, Inc. (RNA) the Best Performing Long Term Stock in 2024?
RNA

Insider Monkey

6 months ago

Is Avidity Biosciences, Inc. (RNA) the Best Performing Long Term Stock in 2024?

Is Avidity Biosciences Inc. (RNA) the Best Performing Small-Cap Stock in 2024?
RNA

Insider Monkey

6 months ago

Is Avidity Biosciences Inc. (RNA) the Best Performing Small-Cap Stock in 2024?

Avidity Biosciences to Participate in Upcoming Investor Conference
RNA

PR Newswire

6 months ago

Avidity Biosciences to Participate in Upcoming Investor Conference

RNA

MT Newswires

6 months ago

Goldman Sachs Initiates Avidity Biosciences at Buy

Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
RNA

PR Newswire

6 months ago

Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

RNA

MT Newswires

7 months ago

Avidity Biosciences Insider Sold Shares Worth $1,010,043, According to a Recent SEC Filing

Avidity Biosciences Joins Patient and Advocacy Communities in Raising Awareness During National Muscular Dystrophy Awareness Month
RNA

PR Newswire

7 months ago

Avidity Biosciences Joins Patient and Advocacy Communities in Raising Awareness During National Muscular Dystrophy Awareness Month

Avidity Biosciences to Participate in Upcoming Investor Conferences
RNA

PR Newswire

7 months ago

Avidity Biosciences to Participate in Upcoming Investor Conferences

RNA

MT Newswires

7 months ago

Barclays Initiates Avidity Biosciences at Overweight

RNA

MT Newswires

7 months ago

Evercore ISI Trims Price Target on Avidity Biosciences to $53 From $54, Keeps Outperform Rating

Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
RNA

PR Newswire

7 months ago

Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Avidity, Kymera raise fresh funds; Walgreens partners with BARDA
RNA

BioPharma Dive

7 months ago

Avidity, Kymera raise fresh funds; Walgreens partners with BARDA

RNA

MT Newswires

7 months ago

Avidity Biosciences Raises $345.1 Million From Upsized Public Offering

Avidity Biosciences Announces Closing of Upsized Public Offering of Common Stock, Including Full Exercise of Underwriters' Option to Purchase Additional Shares
RNA

PR Newswire

7 months ago

Avidity Biosciences Announces Closing of Upsized Public Offering of Common Stock, Including Full Exercise of Underwriters' Option to Purchase Additional Shares

RNA

MT Newswires

8 months ago

Avidity Biosciences Prices Stock Offering at $41 Per Share

Avidity Biosciences Announces Pricing of Upsized Public Offering of Common Stock
RNA

PR Newswire

8 months ago

Avidity Biosciences Announces Pricing of Upsized Public Offering of Common Stock

RNA

MT Newswires

8 months ago

Avidity Biosciences Plans $250 Million Underwritten Public Offering of Shares

Avidity Biosciences Announces Proposed Public Offering of Common Stock
RNA

PR Newswire

8 months ago

Avidity Biosciences Announces Proposed Public Offering of Common Stock

Company News for Aug 13, 2024
RNA

Zacks

8 months ago

Company News for Aug 13, 2024

Avidity Biosciences, Inc. (RNA) Reports Q2 Loss, Misses Revenue Estimates
RNA

Zacks

8 months ago

Avidity Biosciences, Inc. (RNA) Reports Q2 Loss, Misses Revenue Estimates

RNA

MT Newswires

8 months ago

Avidity Biosciences Q2 Net Loss Narrows, Revenue Drops

How Avidity Biosciences Just Dropped The Hammer On Sarepta Therapeutics
RNA

Investor's Business Daily

8 months ago

How Avidity Biosciences Just Dropped The Hammer On Sarepta Therapeutics

Avidity Biosciences Reports Second Quarter 2024 Financial Results and Recent Highlights
RNA

PR Newswire

8 months ago

Avidity Biosciences Reports Second Quarter 2024 Financial Results and Recent Highlights

RNA

MT Newswires

8 months ago

Chardan Research Adjusts Avidity Biosciences' PT to $60 From $45, Keeps Buy Rating

RNA

MT Newswires

8 months ago

Avidity Biosciences Says Del-zota Shows 'Significant' Dystrophin Production in Phase 1/2 Study

Avidity Biosciences Announces Positive AOC 1044 Data Demonstrated Significant Increase of 25% in Dystrophin Production and Reduction of Creatine Kinase Levels to Near Normal in People Living with Duchenne Muscular Dystrophy Amenable to Exon 44 Skipping in the Phase 1/2 EXPLORE44™ Trial
RNA

PR Newswire

8 months ago

Avidity Biosciences Announces Positive AOC 1044 Data Demonstrated Significant Increase of 25% in Dystrophin Production and Reduction of Creatine Kinase Levels to Near Normal in People Living with Duchenne Muscular Dystrophy Amenable to Exon 44 Skipping in the Phase 1/2 EXPLORE44™ Trial

RNA

MT Newswires

8 months ago

Avidity Biosciences Insider Sold Shares Worth $1,213,822, According to a Recent SEC Filing

Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
RNA

PR Newswire

8 months ago

Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Avidity Biosciences Announces Appointment of John B. Moriarty, Jr. as Chief Legal Officer
RNA

PR Newswire

8 months ago

Avidity Biosciences Announces Appointment of John B. Moriarty, Jr. as Chief Legal Officer

3 Russell 2000 Growth Stocks That Could Be Worth the Risk
RNA

Motley Fool

8 months ago

3 Russell 2000 Growth Stocks That Could Be Worth the Risk

Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
RNA

PR Newswire

8 months ago

Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Avidity’s FSHD drug del-brax shows promise in Phase I/II trial
RNA

Clinical Trials Arena

9 months ago

Avidity’s FSHD drug del-brax shows promise in Phase I/II trial

Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
RNA

PR Newswire

9 months ago

Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

RNA

MT Newswires

9 months ago

Avidity Biosciences Insider Sold Shares Worth $1,255,040, According to a Recent SEC Filing

Avidity Biosciences Partners with the FSHD Society to Raise Awareness of Facioscapulohumeral Muscular Dystrophy on World FSHD Day
RNA

PR Newswire

9 months ago

Avidity Biosciences Partners with the FSHD Society to Raise Awareness of Facioscapulohumeral Muscular Dystrophy on World FSHD Day

Estimating The Intrinsic Value Of Avidity Biosciences, Inc. (NASDAQ:RNA)
RNA

Simply Wall St.

9 months ago

Estimating The Intrinsic Value Of Avidity Biosciences, Inc. (NASDAQ:RNA)

Avidity Biosciences, Inc. Announces Closing of Upsized Public Offering of Common Stock, Including Full Exercise of Underwriters' Option to Purchase Additional Shares
RNA

PR Newswire

10 months ago

Avidity Biosciences, Inc. Announces Closing of Upsized Public Offering of Common Stock, Including Full Exercise of Underwriters' Option to Purchase Additional Shares

Avidity Biosciences to Participate in Upcoming Investor Conference
RNA

PR Newswire

10 months ago

Avidity Biosciences to Participate in Upcoming Investor Conference

RNA

MT Newswires

10 months ago

Wells Fargo Raises Price Target on Avidity Biosciences to $75 From $50, Maintains Overweight Rating

RNA

MT Newswires

10 months ago

Avidity Biosciences Prices $400.9 Million Offering of Shares

Avidity Biosciences, Inc. Announces Pricing of Public Offering of Common Stock
RNA

PR Newswire

10 months ago

Avidity Biosciences, Inc. Announces Pricing of Public Offering of Common Stock

Avidity (RNA) Up 33% on Rare Muscle Disease Study Results
RNA

Zacks

10 months ago

Avidity (RNA) Up 33% on Rare Muscle Disease Study Results

RNA

MT Newswires

10 months ago

Avidity Biosciences Plans $300 Million Common Stock Offering

The 'Impressive' Results That Sent Top 1% Avidity Biosciences To A Record
RNA

Investor's Business Daily

10 months ago

The 'Impressive' Results That Sent Top 1% Avidity Biosciences To A Record

Avidity Biosciences, Inc. Announces Proposed Public Offering of Common Stock
RNA

PR Newswire

10 months ago

Avidity Biosciences, Inc. Announces Proposed Public Offering of Common Stock

RNA

MT Newswires

10 months ago

Sector Update: Health Care Stocks Softer Wednesday Afternoon

RNA

MT Newswires

10 months ago

Update: Avidity Biosciences Shares Jump as Muscle Disease Therapy Shows Promising Early Results

RNA

MT Newswires

10 months ago

Top Midday Gainers

RNA

MT Newswires

10 months ago

Chardan Raises Price Target on Avidity Biosciences to $45 From $33, Maintains Buy Rating

Share on Social Networks: